The long-term use of statins is associated with a decreased incidence of adenomatous colon polyps

Digestion

Volumn 79, Issue 1, 2009, Pages 17-22

  Siddiqui, Ali A ^a,b   Nazario, Hector ^a,b   Mahgoub, Amar ^a,b   Pandove, Sandeep ^b   Cipher, Daisha ^c   Spechler, Stuart J ^a,b  

^a VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c Dallas Veterans Affairs Research Corporation   (United States)

Author keywords

3 Hydroxy 3 methyl glutaryl coenzyme A inhibitors; Adenomatous polyps; Colorectal cancer

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; NONSTEROID ANTIINFLAMMATORY AGENT; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; ARTICLE; COLON ADENOMA; COLON POLYP; COLONOSCOPY; CONTROLLED STUDY; DRUG USE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; TUMOR VOLUME;

ADENOMATOUS POLYPS; CHI-SQUARE DISTRIBUTION; COLONIC POLYPS; COLONOSCOPY; COLORECTAL NEOPLASMS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; LOGISTIC MODELS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; VETERANS;

EID: 60749087626     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000203636     Document Type: Article

References (22)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
2. Kronborg O, Fenger C: Prognostic evaluation of planned follow-up in patients with colorectal adenomas. An interim report. Int J Colorectal Dis 1987; 2: 203-207.
3. Thiis-Evensen E, Hoff GS, Sauar J, Langmark F, Majak BM, Vatn MH: Populationbased surveillance by colonoscopy: effect on the incidence of colorectal cancer. Telemark Polyp Study I. Scand J Gastroenterol 1999; 34: 414-420.
4. Atkin WS, Morson BC, Cuzick J: Long-term risk of colorectal cancer after excision of rectosigmoid adenomas. N Engl J Med 1992; 326: 658-662.
5. Thun MJ, Namboodiri MM, Heath CW Jr: Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991; 325: 1593-1596.
6. Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Stolley PD, Shapiro S: A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst 1991; 83: 355-358.
7. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, Petrelli N, Pipas JM, Karp DD, Loprinzi CL, Steinbach G, Schilsky R: A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003; 348: 883-890.
8. Wong WW, Dimitroulakos J, Minden MD, Penn LZ: HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 2002; 16: 508-519.
9. Jakobisiak M, Golab J: Potential antitumor effects of statins (review). Int J Oncol 2003; 23: 1055-1069.
10. Carlberg M, Dricu A, Blegen H, Wang M, Hjertman M, Zickert P, Hoog A, Larsson O: Mevalonic acid is limiting for N-linked glycosylation and translocation of the insulinlike growth factor-1 receptor to the cell surface. Evidence for a new link between 3-hydroxy-3-methylglutaryl-coenzyme A reductase and cell growth. J Biol Chem 1996; 271: 17453-17462.
11. Narisawa T, Morotomi M, Fukaura Y, Hasebe M, Ito M, Aizawa R: Chemoprevention by pravastatin, a 3-hydroxy-3-methylglutarylcoenzyme A reductase inhibitor, of N-methyl-N-nitrosourea-induced colon carcinogenesis in F344 rats. Jpn J Cancer Res 1996; 87: 798-804.
12. Agarwal B, Rao CV, Bhendwal S, Ramey WR, Shirin H, Reddy BS, Holt PR: Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac. Gastroenterology 1999; 117: 838-847.
13. Poynter JN, Gruber SB, Higgins PD, Almog R, Bonner JD, Rennert HS, Low M, Greenson JK, Rennert G: Statins and the risk of colorectal cancer. N Engl J Med 2005; 352: 2184-2192.
14. Winawer SJ, Zauber AG, Ho MN, O'Brien MJ, Gottlieb LS, Sternberg SS, Waye JD, Schapiro M, Bond JH, Panish JF: Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 1993; 329: 1977-1981.
15. O'Shaughnessy JA, Kelloff GJ, Gordon GB, Dannenberg AJ, Hong WK, Fabian CJ, Sigman CC, Bertagnolli MM, Stratton SP, Lam S, Nelson WG, Meyskens FL, Alberts DS, Follen M, Rustgi AK, Papadimitrakopoulou V, Scardino PT, Gazdar AF, Wattenberg LW, Sporn MB, Sakr WA, Lippman SM, Von Hoff DD: Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res 2002; 8: 314-346.
16. Pfeffer MA, Keech A, Sacks FM, Cobbe SM, Tonkin A, Byington RP, Davis BR, Friedman CP, Braunwald E: Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project. Circulation 2002; 105: 2341-2346.
17. Ladabaum U, Chopra CL, Huang G, Scheiman JM, Chernew ME, Fendrick AM: Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer. A cost-effectiveness analysis. Ann Intern Med 2001; 135: 769-781.
18. Bonovas S, Filioussi K, Flordellis CS, Sitaras NM: Statins and the risk of colorectal cancer: a meta-analysis of 18 studies involving more than 1.5 million patients. J Clin Oncol 2007; 25: 3462-3468.
19. Coogan PF, Smith J, Rosenberg L: Statin use and risk of colorectal cancer. J Natl Cancer Inst 2007; 99: 32-40.
20. Kaye JA, Jick H: Statin use and cancer risk in the General Practice Research Database. Br J Cancer 2004; 90: 635-637.
21. Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar HJ: The risk of cancer in users of statins. J Clin Oncol 2004; 22: 2388-2394.
22. Swamy MV, Cooma I, Reddy BS, Rao CV: Lamin B, caspase-3 activity, and apoptosis induction by a combination of HMG-CoA reductase inhibitor and COX-2 inhibitors: a novel approach in developing effective chemopreventiveregimens. Int J Oncol 2002; 20: 753-759.